Back to Search

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

  • Protocol Number: 202205024
  • Principal Investigator: Kim, Hyun
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions